secwatch.observer — SEC 8-K summary
======================================

Issuer:     Praxis Precision Medicines, Inc. (PRAX)
CIK:        0001689548
Form:       8-K
Filed at:   2023-10-02T23:59:59+00:00
Accession:  0001689548-23-000133
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Praxis Precision updates clinical pipeline at R&D Day; ulixacaltamide NDA plan 2025
--------------------------------------------------------------------------------

- Ulixacaltamide: 55% vs 31% patients achieved ≥3-point mADL11 improvement (p=0.023) in Essential1.
- FDA confirmed mADL11 as primary endpoint for Phase 3 Essential3; NDA submission expected in 2025.
- PRAX-222 EMBRAVE Part 1 dosing nearly complete; no treatment-related SAEs; 44% median seizure reduction.
- PRAX-628 Phase 1 data show sustained brain activity; Phase 2 PPR study results expected Q4 2023.
- PRAX-562 EMBOLD study ongoing; topline results from pediatric epilepsy study expected H1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689548/000168954823000133/0001689548-23-000133-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689548/000168954823000133/prax-20231002.htm
  HTML page:      https://secwatch.observer/filing/0001689548-23-000133

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer